These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 12920412

  • 1. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M, McGrath PJ, Sheu WP, Reboxetine Study Group.
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [Abstract] [Full Text] [Related]

  • 2. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Aug; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 3. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

  • 4. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
    Lee MS, Ham BJ, Kee BS, Kim JB, Yeon BK, Oh KS, Oh BH, Lee C, Jung HY, Chee IS, Choe BM, Paik IH.
    Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
    [Abstract] [Full Text] [Related]

  • 5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 7. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, Lineberry CG.
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S, Bodlund O, Agren H.
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [Abstract] [Full Text] [Related]

  • 9. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T.
    Biol Psychiatry; 2006 Jun 01; 59(11):1052-60. PubMed ID: 16581036
    [Abstract] [Full Text] [Related]

  • 10. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M.
    J Clin Pharm Ther; 2005 Apr 01; 30(2):133-8. PubMed ID: 15811165
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan 01; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis.
    Zajecka JM, Jeffries H, Fawcett J.
    J Clin Psychiatry; 1995 Aug 01; 56(8):338-43. PubMed ID: 7635848
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 01; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 14. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U, Onder E.
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec 01; 253(6):307-12. PubMed ID: 14714120
    [Abstract] [Full Text] [Related]

  • 15. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
    López-Muñoz F, Rubio G, Alamo C, García-García P, Pardo A.
    Clin Neuropharmacol; 2006 Dec 01; 29(4):192-6. PubMed ID: 16855420
    [Abstract] [Full Text] [Related]

  • 16. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.
    Rampello L, Alvano A, Chiechio S, Raffaele R, Vecchio I, Malaguarnera M.
    Arch Gerontol Geriatr; 2005 Dec 01; 40(3):275-85. PubMed ID: 15814161
    [Abstract] [Full Text] [Related]

  • 17. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
    Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE.
    Int Clin Psychopharmacol; 2003 May 01; 18(3):151-6. PubMed ID: 12702894
    [Abstract] [Full Text] [Related]

  • 18. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug 01; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 19. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C, Sivrioglu EY, Akgoz S, Eker SS, Kirli S.
    Hum Psychopharmacol; 2006 Jul 01; 21(5):337-45. PubMed ID: 16856215
    [Abstract] [Full Text] [Related]

  • 20. Use of reboxetine in bulimia nervosa: a pilot study.
    Fassino S, Daga GA, Boggio S, Garzaro L, Pierò A.
    J Psychopharmacol; 2004 Sep 01; 18(3):423-8. PubMed ID: 15358988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.